MPM Bioimpact LLC Has $7.57 Million Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK)

MPM Bioimpact LLC lifted its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 43.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 685,826 shares of the company’s stock after buying an additional 206,374 shares during the quarter. MPM Bioimpact LLC owned about 1.29% of Stoke Therapeutics worth $7,565,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. JPMorgan Chase & Co. boosted its position in shares of Stoke Therapeutics by 29.2% during the 4th quarter. JPMorgan Chase & Co. now owns 19,964 shares of the company’s stock valued at $220,000 after purchasing an additional 4,512 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in Stoke Therapeutics by 2.9% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,350,925 shares of the company’s stock valued at $14,901,000 after buying an additional 38,446 shares during the period. Barclays PLC boosted its holdings in shares of Stoke Therapeutics by 145.3% during the 3rd quarter. Barclays PLC now owns 79,740 shares of the company’s stock worth $980,000 after buying an additional 47,239 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Stoke Therapeutics by 1.4% during the 4th quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company’s stock worth $1,028,000 after buying an additional 1,330 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in shares of Stoke Therapeutics during the 4th quarter worth approximately $1,423,000.

Analyst Upgrades and Downgrades

STOK has been the topic of a number of research reports. Chardan Capital reiterated a “buy” rating and set a $24.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, April 9th. Finally, HC Wainwright reissued a “buy” rating and set a $47.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Stoke Therapeutics presently has an average rating of “Buy” and an average target price of $25.60.

Stoke Therapeutics Price Performance

STOK opened at $8.93 on Wednesday. The firm has a market capitalization of $487.55 million, a P/E ratio of -4.25 and a beta of 1.20. Stoke Therapeutics, Inc. has a fifty-two week low of $5.35 and a fifty-two week high of $17.58. The company’s 50-day moving average is $8.07 and its 200 day moving average is $10.02.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Tuesday, May 13th. The company reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $2.27. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. On average, equities research analysts expect that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Insider Activity

In other news, insider Barry Ticho sold 3,884 shares of the stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the transaction, the insider now directly owns 63,962 shares of the company’s stock, valued at $554,550.54. This represents a 5.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the sale, the director now directly owns 148,253 shares in the company, valued at $1,285,353.51. This trade represents a 6.54% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 16,532 shares of company stock valued at $143,332 in the last ninety days. 11.30% of the stock is currently owned by insiders.

Stoke Therapeutics Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.